Amulet Capital Announces Sale of SSI Strategy to Clinigen

Audio By Carbonatix

GREENWICH, Conn.--(BUSINESS WIRE)--Sep 29, 2025--

Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced the sale of SSI Strategy (“SSI”), a trusted strategic consulting partner to biotech innovators, to Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle. Financial terms of the transaction were not disclosed.

Since partnering with Amulet in 2020, SSI has significantly enhanced and broadened its offerings through organic service line expansions, as well as completing a number of targeted, strategic acquisitions.

Today, SSI provides a fully integrated offering to address medical, clinical, regulatory, safety and organizational challenges at all stages of drug development. The company serves a diverse and growing biotech client base from early development through launch across a comprehensive range of scientific functions, including clinical development, clinical operations, strategic program management, regulatory strategy, medical affairs, safety and evidence and value. SSI’s innovative model and consistent double-digit growth have established it as a trusted leader in the biotech ecosystem, now poised to expand further with Clinigen.

SSI is led by CEO Doug Locke and a highly collaborative leadership team comprised of scientific experts, biotech executives and management consultants dedicated to delivering best-in class client services, driving scientific advancement and achieving transformative market-facing outcomes.

“We are proud of our partnership with Doug and the entire SSI team, which epitomizes our approach to value creation,” said Avi Uttamchandani, Partner at Amulet. “We saw a unique opportunity to bring together clinical, medical and rigorous business leadership capabilities in a novel way to address the most important scientific and strategic needs of biotech clients globally. With SSI’s full-service offering and scalable platform, the company today is well positioned to continue serving as a critical partner for its biotech clients from pre-clinical to launch.”

Doug Locke, CEO of SSI Strategy, commented, “SSI has evolved into a global partner across the full drug development lifecycle, and I am excited to continue leading this next phase alongside Clinigen’s leadership. Amulet’s partnership allowed us to not only think bigger for our clients, but gave us the resources and capabilities to execute on our shared vision to become a first-of-its-kind, scaled, global drug development consultancy. We are grateful for their partnership, and we believe we are better positioned than ever to deliver for biotechs in this new chapter as part of the Clinigen family.”

“SSI’s first-to-market offering represents a unique demand generation model that anticipates the complex needs of biotech clients across the development cycle and is able to deliver trusted advice and integrated solutions,” said Ramsey Frank, Managing Partner at Amulet. “This innovative approach and one-stop offering continues to drive strong outperformance and has led to consistent, double-digit revenue growth year over year. We look forward to following SSI’s success as they begin a new partnership with Clinigen, an organization that shares its values and mission.”

Guggenheim Securities and Harris Williams acted as financial advisors to SSI on the transaction, and Davis Polk & Wardwell LLP provided legal counsel.

About Amulet Capital Partners

Amulet Capital Partners is a middle-market private equity investment firm based in Greenwich, CT, and Walnut Creek, CA, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in healthcare companies, focusing on those segments it believes have the most attractive long-term fundamentals. Amulet currently manages approximately $3.1 billion in assets and is investing out of its third fund, which was oversubscribed and closed in July 2024 with approximately $1.2 billion in capital commitments. For additional information, please visit www.amuletcapital.com.

About SSI Strategy

SSI Strategy is dedicated to building better biotechs by combining sharp business acumen with deep expertise in Clinical Development & Operations, Regulatory Affairs, Pharmacovigilance, Medical Affairs, Quality, and more. With an adaptive model that scales to each client’s needs, SSI works as an embedded extension of internal teams—empowering employees, enhancing performance, and accelerating progress. From concept to commercialization, SSI delivers the strategic insight, technical expertise, and collaborative support biotech leaders need to overcome challenges and bring life-saving therapies to patients.

SSI Strategy is headquartered in Morristown, NJ, with offices in London, Munich, and Stockholm. For more information on SSI Strategy, please visit www.ssistrategy.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250928613145/en/

CONTACT: For Amulet:

Erik Carlson / Madeline Jones

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449For SSI:

Denise Strömquist

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH FINANCE MANAGED CARE ASSET MANAGEMENT BIOTECHNOLOGY

SOURCE: Amulet Capital Partners, LP

Copyright Business Wire 2025.

PUB: 09/29/2025 07:00 AM/DISC: 09/29/2025 06:59 AM

http://www.businesswire.com/news/home/20250928613145/en